## This Page Is Inserted by IFW Operations and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representation of The original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

## IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2002 ACS L3

1988:55768 HCAPLUS AN

108:55768 DN

Preparation of new neothramycin derivatives and their use as antibiotics ΤI and antitumor agents

ΙN Langlois, Nicole; Andriamialisoa, Ratremaniaina Z.

PA Centre National de la Recherche Scientifique, Fr.

SO Fr. Demande, 41 pp. CODEN: FRXXBL

DTPatent

LΑ French

CNT 1

PAN.	CNT I				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2586683	A1	19870306	FR 1985-12882	19850829 <
	FR 2586683	В1	19880701		
	GR GRANGE 100 FFR 60				

CASREACT 108:55768 OS

GΙ

$$R^{4}$$
 $R^{5}$ 
 $R^{6}$ 
 $R^{7}$ 
 $R^{4}$ 
 $R^{7}$ 
 $R^{4}$ 
 $R^{5}$ 
 $R^{7}$ 
 $R^{7}$ 
 $R^{4}$ 
 $R^{7}$ 
 $R^{7}$ 
 $R^{7}$ 
 $R^{7}$ 
 $R^{7}$ 
 $R^{8}$ 
 $R^{7}$ 
 $R^{7}$ 
 $R^{8}$ 
 $R^{7}$ 
 $R^{8}$ 
 $R^{7}$ 
 $R^{7}$ 
 $R^{8}$ 
 $R^{7}$ 
 $R^{8}$ 
 $R^{7}$ 
 $R^{8}$ 
 $R^{7}$ 
 $R^{8}$ 
 $R^{7}$ 
 $R^{8}$ 
 $R^{7}$ 
 $R^{8}$ 
 $R^{9}$ 
 $R^{9}$ 
 $R^{9}$ 
 $R^{9}$ 
 $R^{9}$ 
 $R^{9}$ 

$$R^{4}$$
 $NO_{2}$ 
 $R^{8}$ 
 $NO_{2}$ 
 $R^{8}$ 
 $R_{4}$ 
 $NO_{2}$ 
 $R_{1}$ 
 $R_{2}$ 
 $R_{3}$ 
 $R_{4}$ 
 $R_{1}$ 
 $R_{2}$ 
 $R_{3}$ 
 $R_{4}$ 
 $R_{1}$ 
 $R_{2}$ 
 $R_{3}$ 
 $R_{4}$ 
 $R_{5}$ 
 $R_{1}$ 
 $R_{2}$ 
 $R_{7}$ 
 $R_{1}$ 
 $R_{2}$ 
 $R_{3}$ 
 $R_{4}$ 
 $R_{5}$ 
 $R_{1}$ 
 $R_{2}$ 
 $R_{5}$ 
 $R_{1}$ 
 $R_{2}$ 
 $R_{3}$ 
 $R_{4}$ 
 $R_{5}$ 
 $R_{5}$ 
 $R_{1}$ 
 $R_{2}$ 
 $R_{3}$ 
 $R_{4}$ 
 $R_{5}$ 
 $R_{5}$ 
 $R_{1}$ 
 $R_{2}$ 
 $R_{5}$ 
 $R_{5}$ 
 $R_{1}$ 
 $R_{2}$ 
 $R_{5}$ 
 $R_{5}$ 
 $R_{1}$ 
 $R_{2}$ 
 $R_{5}$ 
 $R_{5}$ 
 $R_{1}$ 
 $R_{5}$ 
 $R_{5}$ 
 $R_{5}$ 
 $R_{1}$ 
 $R_{2}$ 
 $R_{5}$ 
 $R_{5}$ 
 $R_{1}$ 
 $R_{5}$ 
 $R$ 

The title compd. (I; II; R1, R2 = H, OH, alkoxy, alkanoyl, or R1R2 = CO; AΒ R3, R4, R5 = H, halo, OH, alkoxy, alkanoyl, or any two of them = OCH2O; R6 = H, alkyl, alkanoyl; R7 = H, OH, alkoxy, alkanoyl, HS, alkylthio, cyano, etc.), useful as antibiotics and antitumors, are prepd. N-Benzoylpyrrolidine III (R1 = MeO, R2 = R3 = R4 = R5 = H, R8 = CHO), prepd. in several steps via the appropriate N-[(epoxypentyl)benzamide IV and III (R8 = CH2OH), in MeOH/EtOAc was hydrogenated over Raney Ni over 0.5 h to give 62% the corresponding II. I were active against sarcoma 180 and P 388 and L 1210 leukemia cells (exptl. details not described.).

IT**67-56-1**, reactions

RL: RCT (Reactant)

(addn. reaction of, with cyanobutene)

RN 67-56-1 HCAPLUS

CN Methanol (8CI, 9CI) (CA INDEX NAME)

нзс-он

IT 592-51-8 RL: RCT (Reactant) (addn. reaction of, with methanol) 592-51-8 HCAPLUS RN CN 4-Pentenenitrile (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)  $H_2C = CH - CH_2 - CH_2 - CN$ IT 67040-46-4 RL: RCT (Reactant) (amidation by, of benzoyl chloride deriv.) RN67040-46-4 HCAPLUS 2-Pyrrolidinone, 5-[(1-ethoxyethoxy)methyl]- (9CI) (CA INDEX NAME) CNOEt IT 610-14-0, o-Nitrobenzoyl chloride RL: RCT (Reactant) (amidation of, by methoxypentenylimine) RN 610-14-0 HCAPLUS CN Benzoyl chloride, 2-nitro- (9CI) (CA INDEX NAME) ΙT 104783-94-0P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and amidation by, of benzoyl chloride deriv.) RN 104783-94-0 HCAPLUS 4-Pentenimidic acid, methyl ester, hydrochloride (9CI) (CA INDEX NAME) CN NH  $MeO-C-CH_2-CH_2-CH=-CH_2$ HC1 ΙT 2426-84-8P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and oxidn. of) RN 2426-84-8 HCAPLUS

CN Benzaldehyde, 5-methoxy-2-nitro-4-(phenylmethoxy)- (9CI) (CA INDEX NAME)

IT 59593-15-6P 59593-16-7P 104769-69-9P 104833-50-3P 112433-78-0P 112433-79-1P 112459-02-6P 112459-03-7P

RN 59593-15-6 HCAPLUS

CN 5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one, 1,2,3,11a-tetrahydro-3,8-dihydroxy-7-methoxy-, (3R,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 59593-16-7 HCAPLUS

CN 5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one, 1,2,3,11a-tetrahydro-3,8-dihydroxy-7-methoxy-, (3S,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 104769-69-9 HCAPLUS

CN 5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one, 1,2,3,1la-tetrahydro-3-methoxy-, (3R-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 104833-50-3 HCAPLUS

CN 5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one, 1,2,3,11a-tetrahydro-3-methoxy-, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 112433-78-0 HCAPLUS

CN 1H-Pyrrolo[2,1-c][1,4]benzodiazepine-11-sulfonic acid, 2,3,5,10,11,11a-hexahydro-3-methoxy-5-oxo-, monosodium salt (9CI) (CA INDEX NAME)

Na

RN 112433-79-1 HCAPLUS

CN 5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one, 1,2,3,11a-tetrahydro-3,7-dimethoxy- (9CI) (CA INDEX NAME)

RN 112459-02-6 HCAPLUS RN 112459-03-7 HCAPLUS

CN 5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one, 1,2,3,11a-tetrahydro-3-methoxy-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

$$\stackrel{\text{OMe}}{\stackrel{\text{OMe}}{\stackrel{\text{O}}}{\stackrel{\text{O}}{\stackrel{\text{O}}{\stackrel{\text{O}}{\stackrel{\text{O}}{\stackrel{\text{O}}{\stackrel{\text{O}}}{\stackrel{\text{O}}{\stackrel{\text{O}}}{\stackrel{\text{O}}{\stackrel{\text{O}}{\stackrel{\text{O}}}{\stackrel{\text{O}}{\stackrel{\text{O}}}{\stackrel{\text{O}}}{\stackrel{\text{O}}}{\stackrel{\text{O}}}{\stackrel{\text{O}}{\stackrel{\text{O}}}{\stackrel{\text{O}}}{\stackrel{\text{O}}}{\stackrel{\text{O}}}{\stackrel{\text{O}}}{\stackrel{\text{O}}}{\stackrel{\text{O}}}{\stackrel{\text{O}}}{\stackrel{\text{O}}}{\stackrel{\text{O}}}{\stackrel{\text{O}}}{\stackrel{\text{O}}}}{\stackrel{\text{O}}}{\stackrel{\text{O}}}{\stackrel{\text{O}}}{\stackrel{\text{O}}}{\stackrel{\text{O}}}}\stackrel{\text{O}}{\stackrel{\text{O}}}}\stackrel{\text{O}}}{\stackrel{\text{O}}}}\stackrel{\text{O}}}{\stackrel{\text{O}}}}\stackrel{\text{O}}}{\stackrel{\text{O}}}}\stackrel{\text{O}}}{\stackrel{\text{O}}}\stackrel{\text{O}}}\stackrel{\text{O}}}{\stackrel{\text{O}}}}\stackrel{\text{O}}\stackrel{\text{O}}}\stackrel{\text{O}}}\stackrel{\text{O}}}\stackrel{\text{O}}}\stackrel{\text{O}}}\stackrel{\text{O}}}\stackrel{\text{O}}}\stackrel{\text{O}}}\stackrel{\text{O}}}\stackrel{\text{O}}}\stackrel{\text{O}}}\stackrel{\text{O}}}\stackrel{\text{O}}}\stackrel{\text{O}}\stackrel{\text{O}}}\stackrel{\text{O}}}\stackrel{\text{O}}}\stackrel{\text{O}}}\stackrel{\text{O}}}\stackrel{\text{O}}}\stackrel{\text{O}}}\stackrel{\text{O}}}\stackrel{\text{O}}}\stackrel{\text{O}}\stackrel{\text{O}}}\stackrel{\text{O}}}\stackrel{\text{O}}}\stackrel{\text{O}}$$

RN 105027-00-7 HCAPLUS

CN Benzamide, N-(1-methoxy-4-pentenyl)-2-nitro- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
O & OMe \\
|| & | \\
C-NH-CH-CH_2-CH_2-CH=CH_2
\end{array}$$

$$\begin{array}{c|c}
O & OMe \\
|| & | \\
O & | \\
NO_2
\end{array}$$

RN 105243-50-3 HCAPLUS

CN 2-Pyrrolidinol, 5-[(1-ethoxyethoxy)methyl]-1-(2-nitrobenzoyl)- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} O_2N & & \\ \hline C & O & \\ \hline \\ HO & & \\ \hline \\ CH_2-O-CH-Me \end{array}$$

RN 105243-53-6 HCAPLUS

CN 2-Pyrrolidinol, 5-[(1-ethoxyethoxy)methyl]-1-[5-methoxy-2-nitro-4-(phenylmethoxy)benzoyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} \text{O-CH}_2\text{-Ph} \\ \text{OMe} \\ \text{O}_2\text{N} \\ \text{C} \text{-O} \\ \text{OEt} \\ \text{HO} \\ \text{N} \\ \text{CH}_2\text{-O-CH-Me} \end{array}$$

RN 105243-55-8 HCAPLUS

CN 2-Pyrrolidinecarboxaldehyde, 5-hydroxy-1-[5-methoxy-2-nitro-4-(phenylmethoxy)benzoyl]-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 105308-69-8 HCAPLUS

CN 2-Pyrrolidinemethanol, 5-methoxy-1-(2-nitrobenzoyl)-, (2S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 105308-70-1 HCAPLUS

CN 2-Pyrrolidinemethanol, 5-methoxy-1-(2-nitrobenzoyl)-, (2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 105308-71-2 HCAPLUS

CN 2-Pyrrolidinecarboxaldehyde, 5-methoxy-1-(2-nitrobenzoyl)-, (2S-cis)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 105308-72-3 HCAPLUS

CN 2-Pyrrolidinecarboxaldehyde, 5-methoxy-1-(2-nitrobenzoyl)-, (2S-trans)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 105308-73-4 HCAPLUS

CN 2-Pyrrolidinemethanol, 5-hydroxy-1-[5-methoxy-2-nitro-4-(phenylmethoxy)benzoyl]-, (2S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 105308-74-5 HCAPLUS

CN 2-Pyrrolidinecarboxaldehyde, 5-hydroxy-1-[5-methoxy-2-nitro-4-(phenylmethoxy)benzoyl]-, (2S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 112433-80-4 HCAPLUS

CN 2-Pyrrolidinone, 5-[(1-ethoxyethoxy)methyl]-1-(2-nitrobenzoyl)- (9CI) (CA INDEX NAME)

$$O_2N$$
 $C = O$ 
 $OEt$ 
 $OH_2-O-CH-Me$ 

RN 112433-81-5 HCAPLUS

CN 2-Pyrrolidinemethanol, 5-methyl-1-[5-hydroxy-2-nitro-4-(phenylmethoxy)benzoyl]-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 112433-82-6 HCAPLUS

CN 2-Pyrrolidinemethanol, 5-methoxy-1-[5-methoxy-2-nitro-4-(phenylmethoxy)benzoyl]- (9CI) (CA INDEX NAME)

$$O-CH_2-Ph$$
 $OMe$ 
 $O=O$ 
 $MeO$ 
 $N$ 
 $CH_2-OH$ 

RN 112433-83-7 HCAPLUS

CN 2-Pyrrolidinecarboxaldehyde, 5-methoxy-1-[5-methoxy-2-nitro-4-(phenylmethoxy)benzoyl]- (9CI) (CA INDEX NAME)

$$O-CH_2-Ph$$
 $OMe$ 
 $O=O$ 
 $N$ 
 $CHO$ 

RN 112445-52-0 HCAPLUS
CN 2-Pyrrolidinone, 5-[(1-ethoxyethoxy)methyl]-1-[5-methoxy-2-nitro-4-(phenylmethoxy)benzoyl]- (9CI) (CA INDEX NAME)

RN112459-04-8 HCAPLUS RN112459-05-9 HCAPLUS RN112459-06-0 HCAPLUS RN112459-07-1 HCAPLUS **100-44-7**, reactions IT RL: RCT (Reactant) (O-benzylation by, of nitrovanillin) RN100-44-7 HCAPLUS CN Benzene, (chloromethyl) - (9CI) (CA INDEX NAME)

 $Ph-CH_2-Cl$ 

IT 2454-72-0, 6-Nitrovanillin
RL: RCT (Reactant)
(O-benzylation of)
RN 2454-72-0 HCAPLUS
CN Benzaldehyde, 4-hydroxy-5-methoxy-2-nitro- (9CI) (CA INDEX NAME)